Synergistic antibacterial activity of new isomeric carborane derivatives through combination with nanoscaled titania

Journal of Biomedical Nanotechnology

Volumn 9, Issue 3, 2013, Pages 393-402

  Li, Shuihong ^a   Wu, Changyu ^a   Zhao, Xinqing ^c   Jiang, Hui ^a   Yan, Hong ^b   Wang, Xuemei ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

^c DALIAN UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

A. baumannii; Antibacterial Activity; Carborane Derivatives; Nanoscaled Titania; Synergistic Effect

Indexed keywords

ANTI-BACTERIAL ACTIVITY; BAUMANNII; CARBORANE DERIVATIVES; SYNERGISTIC EFFECT; TITANIA;

BACTERIA; DRUG INTERACTIONS; ORGANOMETALLICS;

TITANIUM DIOXIDE;

CARBORANE DERIVATIVE; FERROCENE DERIVATIVE; NANOPARTICLE; TITANIUM DIOXIDE;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CELL INTERACTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HOSPITAL INFECTION; IN VITRO STUDY; ISOMERISM; MORPHOLOGY; NONHUMAN; SURFACE PROPERTY;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BORANES; COLONY COUNT, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ELECTROCHEMICAL TECHNIQUES; ISOMERISM; MICROBIAL SENSITIVITY TESTS; NANOPARTICLES; PARTICLE SIZE; SPECTROPHOTOMETRY, ULTRAVIOLET; TITANIUM;

EID: 84876517806     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2013.1550     Document Type: Article

References (55)

1. M. L. Joly-Guillou, Clinical impact and pathogenicity of Acinetobacter. Clin. Microbiol. Infect. 11, 868 (2005).
2. M. B. Marques, K. B. Waites, J. E. Mangino, B. B. Hines, and S. A. Moser, Genotypic investigation of multidrug-resistant Acinetobacter baumannii infections in a medical intensive care unit. J. Hosp. Infect. 37, 125 (1997).
3. X. Vila-Farres, C. Garcia de la Maria, R. Lpez-Rojas, J. Pachn, E. Giralt, and J. Vila, In vitro activity of several antimicrobial peptides against colistin-susceptible and colistin-resistant Acinetobacter baumannii. Clin. Microbiol. Infect. 18, 383 (2012).
4. I. P. Day, J. Goudie, K. Nishiki, and P. D. Williams, Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol. Lett. 76, 239 (1995).
5. Q. Guo, S. Sun, J. Yu, Y. Li, and L. Cao, Synergistic activity of azoles with amiodarone against clinically resistant Candida albicans tested by chequerboard and time-kill methods. J. Med. Microbiol. 57, 457 (2008).
6. D. Andes, A. Lepak, J. Nett, L. Lincoln, and K. Marchillo, In vivo fluconazole pharmacodynamics and resistance development in a previously susceptible Candida albicans population examined by microbiologic and transcriptional profiling. Antimicrob. Agents Ch. 50, 2384 (2006).
7. E. Gradelski, B. Kolek, D. P. Bonner, L. Valera, B. Minassian, and J. Fung-Tomc, Activity of gatifloxacin and ciprofloxacin in combination with other antimicrobial agents. Int. J. Antimicrob. Ag. 17, 103 (2001).
8. P. Gilbert and A. J. McBain, Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance. Clin. Microbiol. Rev. 16, 189 (2003).
9. C. Vauthier, C. Dubernet, C. Chauvierre, I. Brigger, and P. Couvreur, Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J. Control Release 93, 151 (2003).
10. J. H. Kim, R. D. Burnett, and A. Gabriel, Stimuli-responsive hollow polymer nanoparticles for use as novel delivery systems. J. Biomed. Nanotechnol. 8, 432 (2012).
11. O. C. Farokhzad, A. Khademhosseini, S. Jon, A. Hermmann, J. Cheng, C. Chin, A. Kiselyuk, B. Teply, G. Eng, and R. Langer, Microfluidic system for studying the interaction of nanoparticles and microparticles with cells. Anal. Chem. 77, 5453 (2005).
12. E. Tamer, and W. Volkmar, Implications of intracellular distribution of nanovesicles for bioimaging studies. J. Biomed. Nanotechnol. 5, 620 (2009).
13. K. Miyata, R. J. Christie, and K. Kataoka, Polymeric micelles for nano-scale drug delivery. React. Funct. Polym. 71, 227 (2011).
14. E. Leo, A. Scatturin, E. Vighi, and A. Dalpiaz, Polymeric nanoparticles as drug controlled release systems: A new formulation strategy for drugs with small or large molecular weight. J. Nanosci. Nanotechnol. 6, 3070 (2006).
15. Q. N. Li, X. M. Wang, X. H. Lu, H. E. Tian, H. Jiang, G. Lv, D. D. Guo, C. H. Wu, and B. A. Chen, The incorporation of daunorubicin in cancer cells through the use of titanium dioxide whiskers. Biomaterials 30, 4708 (2009).
16. A. Kumar, A. K. Pandey, S. S. Singh, R. Shanker, and A. Dhawan, Cellular uptake and mutagenic potential of metal oxide nanoparticles in bacterial cells. Chemosphere 83, 1124 (2011).
17. 2 nanorods on a panel of pathogenic bacteria. J. Biomed. Nanotechnol. 8, 394 (2012).
18. B. K. Bernard, M. R. Osheroff, A. Hofman, and J. H. Mennear, Toxicology and carcinogenesis studies of dietary titanium dioxidecoated mica in male and female Fischer 344 rats. J. Toxicol. Env. Health 29, 417 (1990).
19. D. F. Zhang, B. Jiang, Z. M. Xiang, and S. Y. Wang, Functional characterisation of altered outer membrane proteins for tetracycline resistance in Escherichia coli. Int. J. Antimicrob. Ag. 32, 315 (2008).
20. J. F. Valliant, K. J. Guenther, A. S. King, P. Morel, P. Schaffer, O. Sogbein, and K. A. Stephenson, The medicinal chemistry of carboranes. Coordin. Chem. Rev. 232, 173 (2002).
21. M. F. R. Fouda, M. M. Abd-Elzaher, R. A. Abdelsamaia, and A. A. Labib, On the medicinal chemistry of ferrocene. Appl. Organomet. Chem. 21, 613 (2007).
22. C. H. Wu, H. D. Ye, W. J. Bai, Q. N. Li, D. D. Guo, G. Lv, H. Yan, and X. M. Wang, New potential anticancer agent of carborane derivatives: Selective cellular interaction and activity of ferrocene-substituted dithio-o-carborane conjugates. Bioconjugate Chem. 22, 16 (2011).
23. B. H. Xu, X. Q. Peng, Y. Z. Li, and H. Yan, Reactions of 16e CpCo half-sandwich complexes containing a chelating 1,2-dicarbacloso- dodecaborane-1,2-dichalcogenolate ligand with ethynylferrocene and dimethyl acetylenedicarboxylate. Chem.-Eur. J. 14, 9347 (2008).
24. B. H. Xu, X. Q. Peng, Z. W. Xu, Y. Z. Li, and H. Yan, Cobalt(III)- mediated disulfuration and hydrosulfuration of alkynes. Inorg. Chem. 47, 7928 (2008).
25. J. Szlinder-Richert, B. Cybulska, J. Grzybowska, J. Bolard, and E. Borowski, Interaction of amphotericin B and its low toxic derivative, N-methyl-N-D-fructosyl amphotericin B methyl ester, with fungal, mammalian and bacterial cells measured by the energy transfer method. Farmaco 59, 289 (2004).
26. W. W. Zhang, S. G. Chen, S. Q. Yu, and Y. S. Yin, Experimental and theoretical investigation of the pH effect on the titania phase transformation during the sol-gel process. J. Cryst. Growth 308, 122 (2007).
27. 2 nanostructures and their application in dyesensitized solar cells. J. Nanosci. Nanotechnol. 11, 9846 (2011).
28. M. M. Tunney, G. Ramage, T. R. Field, T. F. Moriarty, and D. G. Storey, Rapid colorimetric assay for antimicrobial susceptibility testing of Pseudomonas aeruginosa. Antimicrob. Agents Ch. 48, 1879e81 (2004).
29. L. Grausova, L. Bacakova, A. Kromka, S. Potocky, M. Vanecek, M. Nesladek, and V. Lisa, Nanodiamond as promising material for bone tissue engineering. J. Nanosci. Nanotechnol. 9, 3524 (2009).
30. R. K. Pettit, C. A. Weber, M. J. Kean, H. Hoffmann, G. R. Pettit, R. Tan, K. S. Franks, and M. L. Horton, Microplate alamar blue assay for Staphylococcus epidermidis biofilm susceptibility testing. Antimicrob. Agents Ch. 49, 2612 (2005).
31. Clinical and Laboratory Standards Institute, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: Approved standard, 8th edn., Document M7-A8, Wayne, PA, CLSI (2008).
32. I. Nyilasi, S. Kocsubé, K. Krizsán, L. Galgóczy, M. Pesti, T. Papp, and C. Vágvölgyi, In vitro synergistic interactions of the effects of various statins and azoles against some clinically important fungi. FEMS Microbiol. Lett. 307, 175 (2010).
33. W. R. Greco, G. Bravo, and J. C. Parsons, The search for synergy: A critical review from a response surface perspective. Pharmacol. Rev. 47, 331 (1995).
34. D. T. A. Te Dorsthorst, P. E. Verweij, J. F. Meis, N. C. Punt, and J. W. Mouton, In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. J. Antimicrob. Ch. 48, 2007 (2004).
35. Z. C. Zhu, Q. S. Wu, P. Chen, and X. H. Yang, One-step synthesis and antibacterial property of water-soluble silver nanoparticles by CGJ bio-template. J. Nanopart. Res. 13, 5347 (2011).
36. P. K. Mukherjee, D. J. Sheehan, C. A. Hitchcock, and M. A. Ghannoum, Combination treatment of invasive fungal infections. Clin. Microbiol. Rev. 18, 163 (2005).
37. R. E. Lewis, M. E. Klepser, and M. A. Pfaller, In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods. Diagn. Micr. Infec. Dis. 36, 101 (2000).
38. R. E. Lewis, D. J. Diekema, S. A. Messer, M. A. Pfaller, and M. E. Klepser, Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. J. Antimicrob. Chemoth. 49, 345 (2002).
39. D. J. Keele, V. C. DeLallo, R. E. Lewis, E. J. Ernst, and M. E. Klepser, Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. Diagn. Micr. Infec. Dis. 41, 121 (2001).
40. M. E. Klepser, D. Malone, R. E. Lewis, E. J. Ernst, and M. A. Pfaller, Evaluation of voriconazole pharmacodynamics using time- kill methodology. Antimicrob. Agents Ch. 44, 1917 (2000).
41. J. C. Calabrese, L. T. Cheng, J. C. Green, S. R. Marder, and W. Tam, Molecular second-order optical nonlinearities of metallocenes. J. Am. Chem. Soc. 113, 7227 (1991).
42. J. D. Li, M. Chen, H. B. Zhang, and S. Liu, Electrochemical and photochemical characterization of novel ferrocenyl-azobenzene labeled PNA monomers for DNA detection. Inorg. Chem. Commun. 11, 392 (2008).
43. N. Moreau, P. Lacroix, and L. Fournel, Antibiotic uptake by bacteria as measured by partition in polymer aqueous phase systems. Anal. Biochem. 141, 94 (1984).
44. Nikaido, Prevention of drug access to bacterial targets: Permeability barriers and active efflux. Science 264, 382 (1994).
45. H. Nikaido, Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin. Infect. Dis. 27, S32 (1998).
46. A. Mahamoud, J. Chevalier, S. Alibert-Franco, W. V. Kern, and J. Pagès, Antibiotic efflux pumps in gram-negative bacteria: The inhibitor response strategy. J. Antimicrob. Chemoth. 59, 1223 (2007).
47. D. B. Chithrani, Optimization of bio-nano interface using gold nanostructures as a model nanoparticle system. Nanotechnology 1, 115 (2011).
48. Z. Pan, W. Lee, L. Slutsky, R. A. F. Clark, N. Pernodet, and M. H. Rafailovich, Adverse effects of titanium dioxide nanoparticles on human dermal fibroblasts and how to protect cells. Small 5, 511 (2009).
49. Y. Y. Zhao, Y. Tian, Y. Cui, W. W. Liu, W. S. Ma, and X. Y. Jiang, Small molecule-capped gold Nanoparticles as potent antibacterial agents that target gram-negative bacteria. J. Am. Chem. Soc. 132, 12349 (2010).
50. B. D. Chithrani, A. A. Ghazani, and W. C. W. Chan, Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6, 662 (2006).
51. S. L. Zhang, J. Li, G. Lykotrafitis, G. Bao, and S. Suresh, Sizedependent endocytosis of nanoparticles. Adv. Mater. 21, 419 (2009).
52. P. Prasad, J. Cheng, A. Shuhendler, A. M. Rauth, and X. Y. Wu, A novel nanoparticle formulation overcomes multiple types of membrane efflux pumps in human breast cancer cells. Drug Deliv. Transl. Res. 2, 95 (2012).
53. 2 nanoparticles by digestive gland cells of a terrestrial isopod. Environ. Toxicol. Chem. 31, 1083 (2012).
54. H. J. Zhang, H. J, H. P. Wang, J. Zhao, B. A. Chen, and X. M. Wang, Ultrasound mediated drug-loaded nanoparticles crossing cell membranes as a new strategy to reverse cancer multidrug resistance. J. Nanosci. Nanotechnol. 11, 1834 (2011).
55. 2 nanoparticles in anatase and rutile crystal phase. Biol. Trace. Elem. Res. 141, 3 (2011).